(IMCR) Immunocore Holdings plc Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IMCR) Immunocore Holdings plc Complete Analysis Pack
Immunocore’s Business Model, Decoded for Investors and Strategists
Unlock the full strategic blueprint behind Immunocore Holdings plc’s business model. This concise Business Model Canvas shows how the company creates value, partners strategically, and scales in a demanding biotech market. Ideal for investors, analysts, and strategists, the full version offers deeper insight into revenue drivers, cost structure, and growth potential.
Partnerships
Clinical trial sites and investigators
Immunocore Holdings plc relies on hospital and academic clinical trial sites to enroll patients in Phase I/II studies across oncology, HBV, HIV, and autoimmune programs. These investigators run dose escalation, safety checks, and biomarker sampling, which is what turns early data into human proof-of-concept.
This network matters because Immunocore has to generate clean, fast readouts before moving into larger trials, and the company’s 2025 filings show R&D spending still centered on clinical development. Without these sites, the pipeline cannot move from lab signal to patient data.
Contract manufacturing organizations
Immunocore Holdings plc relies on contract manufacturing organizations for GMP active substance and fill-finish supply, including one approved product, KIMMTRAK, plus pipeline batches. This gives access to external capacity without building a full in-house biologics plant, which is important for a company with only one commercial product and a growing clinical pipeline.
HLA-A*02:01 testing laboratories
HLA-A*02:01 testing laboratories are key partners because KIMMTRAK is only for HLA-A*02:01-positive patients, and about 45% to 50% of uveal melanoma patients carry this allele. Labs screen patients before treatment, which helps Immunocore Holdings plc select eligible cases fast and stay within label rules.
Specialty distributors and hospital pharmacies
Immunocore Holdings plc relies on specialty distributors and hospital pharmacies to keep KIMMTRAK moving through oncology centers, where the infusion is given over 30 minutes and only to a narrow metastatic uveal melanoma pool. These partners manage stock, cold-chain-like handling, and site supply, which matters for a biologic used in a small, tightly controlled patient base.
- Hospital-based infusion use
- Inventory and delivery control
- Fits low-volume specialty demand
Research and translational collaborators
Immunocore Holdings plc relies on external research partners in cancer, virology, and immunology to test its ImmTAX platform in real settings, while translational collaborators help validate targets and biomarkers so programs can move from discovery into clinical trials. This matters because Immunocore still had 1 approved product, Kimmtrak, so partner data helps de-risk the rest of the pipeline.
Supports target validation and biomarker work
Speeds discovery to clinic transition
Reduces early R&D uncertainty
Immunocore’s Partner Network Powers KIMMTRAK’s Reach
Immunocore Holdings plc’s key partners are hospital trial sites, CMOs, HLA-A*02:01 labs, and specialty distributors. In 2025, that network still supported 1 marketed product, KIMMTRAK, and a pipeline spanning oncology, HBV, HIV, and autoimmune work.
These partners matter because KIMMTRAK only fits HLA-A*02:01-positive patients, which is about 45% to 50% of metastatic uveal melanoma cases.
| Partner | Role |
|---|---|
| Hospital sites | Patient trials |
| CMOs | GMP supply |
| Labs | Allele screening |
| Distributors | Center delivery |
What is included in the product
Detailed Word Document
A concise, real-company Business Model Canvas for Immunocore Holdings plc, mapping its immunotherapy strategy, partners, customers, and revenue drivers.
Customizable Excel Spreadsheet
Quickly spot how Immunocore’s model addresses biotech pain points with a clear, one-page business snapshot.
Reference Sources
Provides a credible source trail for Immunocore Holdings plc, making key claims easier to verify and decisions easier to defend.
Activities
KIMMTRAK commercialization
Immunocore Holdings plc sells KIMMTRAK, a tebentafusp therapy for unresectable or metastatic uveal melanoma, the rarest adult eye cancer, with about 5,000 U.S. cases a year. Key work is focused on specialist cancer centers, physician education, market access support, and ongoing safety tracking after launch.
TCR bispecific discovery
Immunocore Holdings plc’s TCR bispecific discovery uses engineered ImmTAC therapies to find new targets in solid tumors and infectious diseases, and it is the main engine for future pipeline growth. This work turns the company’s T-cell receptor platform into new preclinical candidates, supporting long-term value beyond its current approved assets.
Clinical development
Immunocore Holdings plc’s clinical development work centers on three Phase I/II programs—IMC-C103C, IMC-F106C, and IMC-I109V—spanning oncology and chronic viral disease. The team runs dose escalation, expansion cohorts, biomarker analysis, and endpoint collection, with the pipeline built around early patient data and safety readouts.
Biologic manufacturing and quality control
Immunocore Holdings plc runs biologic manufacturing under GMP rules, with quality control, batch release, and supply planning as repeat tasks. Its current footprint supports one approved medicine, KIMMTRAK, plus clinical programs, so execution has to cover both commercial demand and trial supply.
- GMP biologic production
- Release testing for each batch
- Supply for clinic and market
Regulatory and pharmacovigilance operations
Immunocore runs regulatory and pharmacovigilance work to keep KIMMTRAK approved, labeled, and monitored across markets. This matters for an infused biologic with long post-marketing duties; KIMMTRAK is approved in the US, EU, and UK, and safety reporting supports its continued use plus trial assets.
- Maintains market approvals and label updates.
- Tracks safety events across all regions.
- Supports KIMMTRAK and pipeline trials.
Immunocore’s 2025 Focus: KIMMTRAK Growth and Pipeline Progress
Immunocore Holdings plc’s key activities are KIMMTRAK commercial execution, TCR bispecific discovery, and Phase I/II clinical development. In 2025, KIMMTRAK remained the core revenue driver while the company advanced IMC-C103C, IMC-F106C, and IMC-I109V.
| Area | 2025 focus |
|---|---|
| KIMMTRAK | Launch, access, safety |
| Discovery | ImmTAC target ID |
| Pipeline | 3 Phase I/II programs |
What You See Is What You Get
Business Model Canvas
The Immunocore Holdings plc Business Model Canvas preview you see here is the exact document you’ll receive after purchase. This isn’t a sample or mockup—it’s a direct view of the real file, with the same structure, content, and formatting. Once you buy, you’ll unlock the full, ready-to-use version in the same professional layout.
Resources
ImmTAC platform
ImmTAC is Immunocore Holdings plc's core proprietary TCR-based platform, designed to spot intracellular antigens through HLA molecules; it powers the approved therapy KIMMTRAK and the company’s pipeline. In 2025, this single platform remained the key value driver behind one marketed product and multiple active programs.
KIMMTRAK approved asset
KIMMTRAK is Immunocore Holdings plc's main marketed asset and the core revenue driver, delivering $259.1 million in net product revenue in 2024. Its approved use in uveal melanoma gives real-world clinical evidence and also supports the value of Immunocore Holdings plc's TCR platform.
Clinical pipeline programs
Immunocore Holdings plc’s key resources are its four clinical pipeline programs IMC-C103C, IMC-F106C, IMC-I109V, and IMC-M113V, which support a multi-indication mix across oncology and infectious disease. This pipeline is the core R&D asset behind near-term value creation, with future autoimmune candidates able to widen the platform further.
Patent and know-how base
Immunocore Holdings plc’s moat is its engineered TCR patent estate and biologic know-how. With 1 approved drug, KIMMTRAK, the patent wall around target selection, linkers, and TCR design helps protect revenue and extend the product life cycle.
- Engineered TCR IP is core.
- Patents shield platform value.
- Know-how is a key asset.
Scientific and commercial workforce
Immunocore Holdings plc relies on a highly skilled scientific and commercial workforce to move its TCR platform from lab to patients, with more than 500 employees across research, clinical, regulatory, manufacturing, and sales. That mix turns platform science into trials, approvals, and product revenue, which is critical in a specialized biotech model.
- Research and clinical execution
- Regulatory and manufacturing control
- Commercial sales conversion
- Over 500 specialist employees
ImmTAC Powers KIMMTRAK’s $259M Revenue and 4-Program Pipeline
Key resources are Immunocore Holdings plc’s ImmTAC platform, KIMMTRAK, and its engineered TCR patent estate. The platform underpins one approved drug and four named clinical programs, while KIMMTRAK generated $259.1 million in net product revenue in 2024 and validates the science.
| Resource | Data |
|---|---|
| ImmTAC platform | Core TCR engine |
| KIMMTRAK | $259.1 million revenue |
| Pipeline | 4 clinical programs |
| Workforce | 500+ employees |
Value Propositions
First approved TCR therapy
KIMMTRAK made Immunocore the first company with an approved TCR-based cancer therapy, a clear class-first edge in a crowded oncology market. That regulatory lead still matters: KIMMTRAK remains the only approved TCR therapy, giving Immunocore a rare clinical and commercial foothold.
HLA-restricted precision targeting
Immunocore Holdings plc’s HLA-restricted precision targeting lets its ImmTAC platform see intracellular antigens once they are presented by HLA molecules, so it can reach targets beyond surface proteins. That widens the addressable biology and supports very specific immune recognition; the company’s first approved product, KIMMTRAK, shows this HLA-A*02:01 approach in real use.
Off-the-shelf biologic treatment
KIMMTRAK is a ready-made infused biologic, not a personalized cell therapy, so Immunocore Holdings plc can make it at scale and ship it faster to treatment centers. That cuts the complex, patient-specific manufacturing and chain-of-custody burden seen in autologous therapies, which is key for an ultra-rare cancer market.
Pipeline across 3 disease areas
Immunocore Holdings plc’s pipeline spans 3 disease areas: oncology, infectious disease, and autoimmune disorders. That mix lowers dependence on one indication and widens the platform’s addressable market beyond its current lead asset in uveal melanoma.
- 3 disease areas
- Less single-indication risk
- Broader market reach
Targeted immunosuppression candidates
Immunocore is extending its platform beyond cancer into autoimmune disease with targeted immunosuppression candidates, aiming for precise control of harmful immune activity while preserving broader immune function. This creates a second therapeutic lane beside immune activation, and it matters because the company already has one approved therapy, KIMMTRAK, proving the platform can reach the market.
- Moves from immune activation to immune suppression
- Targets autoimmune disease with precision
- Builds on an approved-platform base
Immunocore’s First-Mover TCR Platform Targets What Others Can’t
Immunocore Holdings plc’s value proposition is a first-mover ImmTAC platform that reaches intracellular targets via HLA, backed by KIMMTRAK, the only approved TCR-based therapy. It pairs precision biology with scalable infusion manufacturing, unlike patient-specific cell therapies.
Its pipeline spans 3 disease areas, so the platform is not tied to one market. That broadens reach while keeping the same core science.
| Value driver | Fact |
|---|---|
| Approved asset | KIMMTRAK, 1st TCR therapy approved |
| Platform reach | 3 disease areas |
| Targeting | HLA-restricted intracellular antigens |
Customer Relationships
Specialist HCP education
Immunocore Holdings plc works closely with oncologists and other specialist clinicians to train them on patient selection, dosing, and safety monitoring for KIMMTRAK, which is approved only for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. That narrow label makes education critical, because correct use directly affects both safety and treatment access.
Clinical-trial investigator support
Immunocore Holdings plc supports clinical-trial investigators with protocol guidance, data capture help, and safety follow-up, which cuts site friction and keeps studies on track. Strong site ties matter: better investigator support usually lifts enrollment speed and retention, helping protect timelines across Immunocore’s 2025 clinical portfolio.
Patient identification via HLA testing
Immunocore’s patient relationship starts with HLA-A*02:01 testing, because KIMMTRAK is only for HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma. This screening step helps filter the right patients early and supports correct use.
The company works with providers through referral pathways and testing awareness, so oncology teams know when to order HLA typing before treatment starts.
Medical affairs and pharmacovigilance
Immunocore Holdings plc keeps tight customer ties through field medical teams and safety staff that stay in contact with prescribers, answer product questions, and manage post-treatment safety reports. For KIMMTRAK, this model fits a specialty biologic with a narrow patient pool, where each treated patient needs close follow-up and rapid adverse-event handling.
- Direct prescriber support
- Safety reporting after treatment
- Best fit for low-volume therapy
Access and reimbursement support
Access and reimbursement support matters for Immunocore Holdings plc because KIMMTRAK is a hospital-administered oncology drug, so payer approval and site onboarding can slow starts. By helping with payer discussions and center setup, Immunocore cuts access friction and supports uptake in a market where reimbursement can decide whether patients get treated.
- Payer approval drives hospital use.
- Center onboarding speeds first doses.
- Lower friction supports adoption.
KIMMTRAK’s Narrow Niche Demands Close Clinician and Payer Ties
Immunocore Holdings plc keeps customer ties tight through specialist oncologist education, HLA-A*02:01 testing, and safety follow-up for KIMMTRAK, its 1 approved product for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. This low-volume model needs close prescriber contact and payer support to get patients treated.
| Customer link | Key fact |
|---|---|
| Target use | 1 labeled cancer setting |
Channels
Hospital oncology infusion centers
Hospital oncology infusion centers are Immunocore Holdings plc’s main channel for KIMMTRAK, the company’s only marketed product, because it must be given in specialist treatment settings. These centers also act as referral hubs for advanced melanoma patients, so access and scheduling drive real use.
Specialty distributors
Immunocore Holdings plc uses specialty distributors for KIMMTRAK, a low-volume, high-complexity biologic sold to a narrow uveal melanoma market. These partners help keep stock available and tightly controlled, which matters when one therapy drives most 2025 product revenue.
Field medical and sales teams
Immunocore Holdings plc uses direct specialist engagement, not mass-market ads, for KIMMTRAK in metastatic uveal melanoma, a rare oncology setting where prescriber education matters more than broad reach. Medical science liaisons and sales teams support oncology centers and key prescribers, which fits a high-touch model with a small eligible patient base and premium drug economics.
Clinical trial networks
Immunocore Holdings plc relies on clinical trial networks of hospitals and academic sites to run early studies. These sites are the main channel for Phase I/II patient enrolment and for generating the clinical evidence needed to support later regulatory approvals.
- Hospital and academic site network
- Phase I/II patient enrolment
- Data for approval filings
Congresses and scientific publications
Peer-reviewed papers and congress talks are a core channel for Immunocore Holdings plc. In 2025, the Company reported $226.1 million in revenue, and those data-led updates help oncologists and investigators trust the ImmTAC platform and move programs into use faster.
- Builds clinical credibility
- Drives oncologist adoption
- Supports pipeline visibility
KIMMTRAK’s Rare-Disease Delivery: Infusion Centers, Distributors, and Field Education
Immunocore Holdings plc sells KIMMTRAK through hospital oncology infusion centers and specialty distributors, because metastatic uveal melanoma needs specialist administration and tight product control. Direct oncology rep and medical science liaison outreach keeps prescribers engaged across a small rare-disease market.
| Channel | Role |
|---|---|
| Infusion centers | Main KIMMTRAK access point |
| Specialty distributors | Stock control and delivery |
| Field medical teams | Prescriber education |
Customer Segments
HLA-A*02:01 positive uveal melanoma patients
HLA-A*02:01-positive uveal melanoma patients are KIMMTRAK’s core commercial segment. The drug is used only in unresectable or metastatic disease, and the HLA-A*02:01 allele is found in about 40%-50% of people of European ancestry, so treatment stays concentrated in specialist oncology teams. Uveal melanoma makes up about 3%-5% of melanoma cases.
Solid tumor oncology centers
Solid tumor oncology centers are core development customers for Immunocore Holdings plc, especially sites treating 8 key cancers: NSCLC, gastric, head and neck, ovarian, synovial sarcoma, melanoma, breast, and endometrial. These centers run trials for IMC-C103C and IMC-F106C, and the same sites could become future launch centers.
Hepatology and infectious disease clinics
Hepatology and infectious disease clinics are the core customers for chronic hepatitis B programs, including IMC-I109V if development succeeds. The World Health Organization estimates about 254 million people live with chronic hepatitis B, and these specialist centers are the ones set up for biomarker testing, viral load tracking, and safety monitoring.
Autoimmune specialist prescribers
Autoimmune specialist prescribers are mainly rheumatologists and dermatologists, plus other specialty-care doctors, because Immunocore Holdings plc’s targeted immunosuppression candidates would be used in complex immune diseases. This is still a development-stage segment, so the near-term base is clinical rather than commercial, with no autoimmune product revenue yet.
- Rheumatology and dermatology lead adoption
- Target users are specialist prescribers
- Segment remains pre-commercial
Payers and hospital formularies
Payers and hospital formularies are key gatekeepers for Immunocore Holdings plc because KIMMTRAK is an infused biologic used in a narrow patient pool, so coverage and formulary status can decide whether treatment starts at all. In the U.S., CMS covered Part B drugs on average at 6% above ASP in 2025, and prior authorization remains common, so access timing and cash collection depend on these buyers.
- Coverage drives patient access
- Formularies shape treatment uptake
- Reimbursement affects revenue timing
Niche cancer base, but a 254M-patient HBV opportunity
Immunocore Holdings plc serves a narrow, specialist base: HLA-A*02:01-positive unresectable or metastatic uveal melanoma patients for KIMMTRAK, plus oncology trial sites for next-gen solid tumor assets. HLA-A*02:01 appears in about 40%-50% of people of European ancestry, and chronic hepatitis B programs target a 254 million-patient global pool.
| Segment | 2025/2026 data |
|---|---|
| Uveal melanoma | 3%-5% of melanoma cases |
| HBV | 254 million people |
Cost Structure
R&D and preclinical spend
R&D and preclinical spend is Immunocore Holdings plc’s biggest long-cycle cost bucket, because discovery, target validation, and lab testing must fund multiple new molecules across oncology and infectious disease at once. In FY2025, this platform model kept R&D as the main cash outflow, with investment focused on IMC001 and other pipeline programs.
Clinical trial operations
Phase I/II clinical trial operations are a major cash drain for Immunocore Holdings plc, with each new expansion cohort or indication adding site fees, monitoring, data management, and biomarker testing. In practice, these studies can run across dozens of sites, and trial execution is what turns IMC products into pipeline value.
Manufacturing and supply chain
Biologic production, fill-finish, QC testing, and logistics are recurring costs, and KIMMTRAK commercial supply keeps cost of goods sold high as volume grows. Immunocore ended FY2024 with about $1.0 billion in cash and investments, which supports tight control of clinical and commercial material through the supply chain.
Sales, marketing, and medical affairs
Immunocore Holdings plc’s sales, marketing, and medical affairs spend is tied to KIMMTRAK’s specialist launch, so it needs field teams, medical science liaisons, payer access support, and medical information. For a niche oncology product, these costs are core to educating prescribers and securing access.
- Field teams support specialist engagement
- Access services help payer uptake
- Medical affairs drives education and info
Regulatory, QA, and IP costs
Regulatory, QA, and IP costs stay high for Immunocore Holdings plc because a T-cell receptor biologics platform needs constant global compliance, safety reporting, batch release, and quality-system upkeep. Patent filing, maintenance, and legal defense also protect the platform’s long life and premium pricing, so these fixed costs are core to the model, not overhead.
- Global compliance and safety reporting
- Quality systems and batch controls
- Patent maintenance and legal defense
Immunocore’s FY2025 Costs: R&D First, Commercial Spend Second
Immunocore Holdings plc’s cost structure is R&D-led, with clinical trials, biologics manufacturing, and regulatory work driving most spend. FY2025 still favored pipeline investment, while commercial costs stayed tied to KIMMTRAK’s specialist launch and access work.
| Cost bucket | FY2025 signal |
|---|---|
| R&D | Main cash outflow |
| Clinical trials | Site and biomarker heavy |
| Supply chain | COGS rises with volume |
Revenue Streams
KIMMTRAK net product sales
KIMMTRAK net product sales are Immunocore Holdings plc's main revenue stream, generated from patients treated in approved markets and the company's key commercial cash engine. In 2025, this product line remained the core driver of sales growth and funding for the pipeline.
U.S. oncology sales
U.S. oncology sales are the main early revenue engine for Immunocore Holdings plc’s approved product, with uptake driven by HLA-A*02:01 specialty melanoma centers and payer coverage. In rare oncology launches, the U.S. often delivers over 50% of early global sales, and KIMMTRAK’s U.S. approval in 2022 keeps it at the center of that base.
Ex-U.S. product sales
Ex-U.S. product sales diversify Immunocore Holdings plc beyond the U.S., with KIMMTRAK approved in Europe, the U.K., Canada, Australia, and Switzerland. As of 2025, this stream is still early, so reimbursement wins and launch execution will decide how fast sales can become material versus U.S. revenue.
Collaboration revenue
Collaboration revenue at Immunocore Holdings plc comes from partnered R&D programs, where biotech partners provide research funding and share development costs. This keeps the platform funded while newer assets move forward, and in 2025 it remained a useful non-product revenue stream alongside core commercial sales.
- Partner funding offsets R&D spend
- Shared risk supports pipeline progress
- Helps fund newer assets
Milestone and royalty income
Milestone and royalty income is a variable, high-margin revenue stream for Immunocore Holdings plc. Cash can arrive when partnered programs hit development or commercial steps, and royalties can follow sales of partnered products, so this line can scale without the same cost base as product revenue.
It depends on partner progress, so timing is uneven, but each payment can lift cash flow fast.
- Paid on development or launch milestones
- Royalties follow partnered product sales
- High-margin, but lumpy cash flow
KIMMTRAK Drives Immunocore’s 2025 Revenue, With Partner Income Supporting R&D
KIMMTRAK net product sales were Immunocore Holdings plc's main revenue stream in 2025, led by U.S. oncology demand and supported by ex-U.S. launches in 5 markets. Collaboration, milestone, and royalty income stayed smaller but added lower-cost, partner-funded cash flow for the pipeline.
| Stream | 2025 role |
|---|---|
| KIMMTRAK sales | Main cash engine |
| U.S. sales | Core launch market |
| Ex-U.S. sales | 5 approved markets |
| Partner income | Funds R&D |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.